flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 clinical (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators 🔴Cardiovascular outcomes with semaglutide by

Rupal Patel Founder & Fractional CMO, Momentum360 Rupal shares practical insights on marketing strategy, lead generation, digital growth, healthcare marketing, and customer acquisition

How to Take PT-141: Routes of Administration Administration routes: PT-141 is a peptide, and like most peptides it is not effective if taken orally (the digestive system would break it down before it could work)

MT-I is legally available for EPP patients with a prescription from a licensed medical professional

2018 AHA/ACC guideline on the management of blood cholesterol

Most available studies were designed to assess cardiovascular or renal outcomes, with neuropathy endpoints evaluated only secondarily